Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced HER2+Breast Cancer × Trastuzumab × Breast × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 556 Neoplasm Metastasis 33 HER2-positive Breast Cancer 29 Breast Neoplasms, Male 27 Neoplasms 16 Brain Neoplasms 16 Inflammatory Breast Neoplasms 15 Stomach Neoplasms 13 Carcinoma, Non-Small-Cell Lung 12 Triple Negative Breast Neoplasms 11 Pancreatic Neoplasms 7 Ovarian Neoplasms 7 Endometrial Neoplasms 7 Colorectal Neoplasms 7 Esophageal Neoplasms 6 Cardiotoxicity 6 Pathologic Complete Response 5 Breast Diseases 5 Squamous Cell Carcinoma of Head and Neck 4 Sarcoma 4 Prostatic Neoplasms 4 Lung Neoplasms 4 HER2-positive Early Breast Cancer 4 Carcinoma, Ductal, Breast 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 HER2-positive Metastatic Breast Cancer 3 HER2 Positive Breast Cancer 3 Carcinoma, Ovarian Epithelial 3 Anatomic Stage I Breast Cancer AJCC v8 3

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡